Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MMP12 | P39900 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633862 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL633480 | 0.91 | SIGMAR1 (0.46) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL633479 | 0.91 | SIGMAR1 (0.46) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL591143 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL590197 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL16179910 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL591583 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL592012 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL592011 | 0.84 | ALDH1A1 (0.52) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 | |
| SCHEMBL1845036 | 0.83 | ALDH1A1 (0.51) | ALDH1A1KMT2ASMN1; SMN2NPSR1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505750-B2 | 5-aminocyclylmethyl-oxazolidin-2-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-29 | — | — | US | disclosed |
| EP-2245028-B1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003789-A1 | 5-AMINOCYCLYLMETHYL-OXAZOLIDIN-2-ONE DERIVATIVES | CNKSR1, KCNH1, CBR3 | ALDH1A1 2633/4885KMT2A 1674/4885SMN1; SMN2 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.